Author Correction: Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.

Saved in:
Bibliographic Details
Title: Author Correction: Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.
Authors: Todo T; Division of Innovative Cancer Therapy, Advanced Clinical Research Center, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. toudou-nsu@umin.ac.jp., Ito H; Division of Innovative Cancer Therapy, Advanced Clinical Research Center, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Ino Y; Division of Innovative Cancer Therapy, Advanced Clinical Research Center, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Ohtsu H; Department of Data Science, National Center for Global Health and Medicine in Japan, Tokyo, Japan.; Leading Center for the Development and Research of Cancer Medicine, Juntendo University, Tokyo, Japan., Ota Y; Department of Pathology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Shibahara J; Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan., Tanaka M; Division of Innovative Cancer Therapy, Advanced Clinical Research Center, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Source: Nature medicine [Nat Med] 2025 Apr; Vol. 31 (4), pp. 1365.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-025-03619-5